Overview

• A division bench dismissed Roche’s injunction appeal, upholding a March 2025 single-judge order that denied interim relief.
• Natco said it will launch its risdiplam immediately at ₹15,900 per bottle and will offer additional discounts through a patient access programme.
• Judges emphasized access to medicine over injunctive patent enforcement and noted Natco’s strong initial challenge to Roche’s patent, reported valid until March 2035.
• Advocacy groups say the roughly 97% price cut from about ₹6–6.2 lakh per bottle could allow purchases under India’s National Policy for Rare Diseases.
• Roche said it was disappointed by the decision and is evaluating options within Indian law while asserting the importance of intellectual property protection.